MDR at the Diagnostic Lab Counter: What Card Acceptance Really Costs a Pathology Centre

Published: 25 October 2026

Category: how-to-guides | cardbuzz

Tags: diagnostic labs, pathology centres, MDR, card acceptance, merchant fees, payment terminals

A patient who walks into a diagnostic lab rarely thinks about what happens after the card is tapped. For the lab, however, that tap sets off a chain of charges, settlements and reconciliations that quietly shape the margin on every test booked. The merchant discount rate, commonly shortened to MDR, is the fee a lab pays for accepting a card payment. It is not a single flat charge in most cases. It is a bundle of interchange paid to the cardholder's bank, assessments paid to the card network, and the acquirer's own margin for providing the terminal, the network connection and the settlement service.

Diagnostic labs make this especially worth understanding. Test packages can be high value compared with everyday retail, so even a small difference in the effective rate adds up across a month of bookings. A centre handling a steady stream of comprehensive panels feels its card costs far more keenly than one handling only occasional low-value tests, which is why the headline rate quoted by a sales representative is rarely the whole story.

The good news is that MDR is manageable once it is understood. It rewards labs that know which card types they accept, how their transactions are routed, and where avoidable costs creep in. This guide explains the mechanics in plain terms, without promising any particular rate, so that a diagnostic centre can have a better conversation with an acquirer.

What MDR Actually Contains

MDR is best thought of as three layers. The first is interchange, which goes to the bank that issued the customer's card. It compensates that bank for funding the transaction, for the interest-free period the cardholder enjoys, and for fraud and credit risk. Interchange varies by card type: a basic debit card, a premium credit card and a commercial card do not carry the same cost, and the lab usually cannot see this split on the receipt.

The second layer is the scheme fee paid to the card network for routing, authorisation and clearing. The third is the acquirer's margin, which covers the terminal hardware or its rental, the software, customer support, chargeback handling and the risk of settling funds before the customer's bank has fully cleared them. When an acquirer quotes a blended rate, all three layers are folded into one figure. When it quotes an interchange-plus arrangement, the layers are shown separately. Neither model is inherently better; the blended model is simpler to budget, while the interchange-plus model is more transparent about what changes when a patient pays with a costlier card.

Why Lab Bookings Cost More to Accept

Diagnostic transactions differ from ordinary retail transactions in ways that matter to cost. First, the average ticket is high, so the absolute fee per transaction is high even when the rate looks modest. Second, premium cards are common in this category, because patients booking comprehensive health packages often hold reward or travel cards and choose to pay by card precisely to earn benefits. Those cards carry higher interchange, which the lab absorbs. Third, health packages are frequently bought on instalments, and instalment transactions carry their own commercial structure that sits alongside ordinary MDR rather than replacing it.

None of this means card acceptance is a bad deal for a diagnostic lab. Cash handling has its own costs in counting, transport, shrinkage and security, and card-paying patients tend to complete higher-value bookings and return for follow-up tests. The point is simply that the cost deserves the same attention as reagent supplies or staff wages, because it is one of the largest variable costs in the business.

Blended Rates Versus Interchange-Plus

A blended rate gives the lab one predictable figure for most card transactions, which makes daily budgeting straightforward. Its drawback is opacity: when a month's statement shows a higher effective rate than expected, it is hard to tell whether the mix of cards changed, whether an extra fee was added, or whether a particular transaction type was priced differently.

An interchange-plus arrangement separates the pass-through costs from the acquirer's margin, so the lab can see exactly how much of each transaction went to interchange and scheme fees. The trade-off is variability: the effective rate moves with the card mix, so a month heavy in premium credit cards will cost more than a month heavy in debit cards. Labs with a finance-savvy owner or accountant often prefer this transparency, while smaller centres often prefer the simplicity of a blended quote. Whichever model is chosen, the lab should ask what is excluded: terminal rental, statement fees, minimum monthly charges, chargeback administration fees and settlement charges can all sit outside the headline rate.

Debit Cards, Credit Cards and UPI in the Mix

The payment mix at the counter directly shapes the monthly bill. Debit cards generally cost less to accept than credit cards, because the issuing bank's funding cost is lower and the regulatory treatment differs. Credit cards cost more, particularly premium variants, but they also enable instalments and higher-value packages that a debit-only centre might lose. Many labs therefore steer patients gently rather than refusing a card type: making the cheaper option the most convenient one at the counter, or explaining the options clearly at booking, can shift the mix over time without turning any patient away.

UPI and other account-to-account methods often carry a different commercial structure again, and their acceptance cost may be lower for the merchant. The sensible approach is to look at the total cost of acceptance across all methods, not at one method in isolation, and to weigh that against the bookings each method enables. A method that looks expensive in isolation may be cheap if it is the method that closes the booking.

Reading the Monthly Statement

The monthly statement is where MDR stops being abstract. A lab should reconcile it in four steps. First, check that the gross card sales on the statement match the terminal's own totals for the month. Second, divide the total fees by gross sales to find the effective rate, and compare it with the quoted rate; a persistent gap is a question to put to the acquirer, not a rounding difference to ignore. Third, look for fees beyond MDR, such as rentals, minimums and chargeback charges, and ask whether each one was disclosed at sign-up. Fourth, check the settlement timing: funds that arrive several working days after the booking create a working-capital cost of their own, particularly for a lab that pays reagent suppliers on short credit.

Keeping a simple spreadsheet of gross sales, fees and effective rate month by month turns this from a chore into a negotiating tool. When an acquirer knows the lab tracks the effective rate, renewal conversations tend to be more honest, and a competing quote can be compared on the same basis rather than on headline figures alone.

Negotiating and Reducing the Cost

Negotiation starts with volume and mix, not with threats to leave. An acquirer prices risk and volume: a centre with steady, growing card turnover, low chargebacks and clean reconciliation is a cheaper customer to serve, and that should be reflected in the rate. Labs can also reduce cost structurally by ensuring transactions are routed correctly, by avoiding manual keyed-entry transactions where a tap or chip read would do, since keyed transactions often price higher and carry more fraud risk, and by training front-desk staff to complete transactions properly the first time so that voids and re-runs do not multiply fees.

It is also worth reviewing the arrangement periodically. Acquirers revise their pricing, new entrants offer different models, and a centre's own mix changes as it grows. A lab that signed up as a small collection centre may now qualify for terms designed for larger chains, and a conversation with the existing acquirer, armed with a year's statements, often produces a better rate without the disruption of changing terminals and settlement accounts.

Closing Thoughts

MDR is not a tax to be resented or a mystery to be ignored. It is the price of a service that lets a diagnostic lab serve patients who arrive without cash, spread payments over time, and book with confidence. Understanding its layers, watching the effective rate, and reviewing the arrangement regularly keeps that price fair. A lab that treats card acceptance as a managed cost, rather than a fixed deduction, protects margin on every test booked and keeps the counter working for both the centre and its patients.